Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Yufeng Wang

Matched on ORCID iD 0009-0003-6701-6525; OpenAlex author ID A5100367914. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 2 papers · 2015: 4 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 13

  1. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting mi… Co-author DOI 10.1016/j.drup.2023.100960↗
  2. TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma. First author DOI 10.3892/mmr.2018.8816↗
  3. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.3892/ijo.2016.3804↗
  4. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through I… Co-author DOI 10.1007/s11523-015-0370-0↗
  5. Cofilin-phosphatase slingshot-1L (SSH1L) is over-expressed in pancreatic cancer (PC) and contributes to tumor cell migration. Co-author DOI 10.1016/j.canlet.2015.02.015↗
  6. Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. First author PMID 25862846↗
  7. High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells. First author PMID 26124331↗
  8. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0109076↗
  9. Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells. Co-author PMID 25202061↗
  10. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells. Co-author PMID 23898070↗
  11. Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Co-author PMID 24222118↗
  12. Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Co-author DOI 10.3892/or.2012.2004↗
  13. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. First author PMID 22641665↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuyuki Nakamura · 11 shared papers, 2012–2017 · strength 0.50
  2. Yasuhiro Kuramitsu · 11 shared papers, 2012–2017 · strength 0.50
  3. Byron Baron · 7 shared papers, 2013–2017 · strength 0.35
  4. Yoshihiko Maehara · 7 shared papers, 2013–2017 · strength 0.33
  5. Rui Lin · 2 shared papers, 2018–2023 · strength 0.25
  6. Baomin Shi · 2 shared papers, 2018–2023 · strength 0.25
  7. Ran Qi · 1 shared paper, 2023 · strength 0.16
  8. Shigeyuki Suenaga · 4 shared papers, 2012–2014 · strength 0.14
  9. Isao Sakaida · 3 shared papers, 2012–2014 · strength 0.10
  10. Masaaki Oka · 2 shared papers, 2012–2015 · strength 0.08
  11. Masayuki Tokunaga · 1 shared paper, 2015 · strength 0.06
  12. Junya Nawata · 1 shared paper, 2014 · strength 0.04
  13. Kumiko Taba · 1 shared paper, 2012 · strength 0.03
  14. Shomei Ryozawa · 1 shared paper, 2012 · strength 0.03
  15. Tomio Ueno · 1 shared paper, 2012 · strength 0.03
  16. Nobuaki Suzuki · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.